Lv5
1188 积分 2024-07-10 加入
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
10小时前
待确认
Meta‐analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma
16小时前
已完结
A first‐line regimen combining Bruton's tyrosine kinase and programmed cell death protein‐1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma
16小时前
已完结
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
1天前
已完结
Combination of ibrutinib with ABT‐199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
1天前
已完结
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
2天前
已完结
Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial
2天前
已完结
Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
2天前
已完结
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies
2天前
已完结
Trogocytosis of chimeric antigen receptors between T cells is regulated by their transmembrane domains
2天前
已完结
皖公网安备34019202002308
